KEYNOTE-057: Pembrolizumab in Patients With High-Risk NMIBC

An overview of the study design, patient populations, and eligibility of the KEYNOTE-057 trial, which studied pembrolizumab in patients with high-risk NMIBC.

Related Videos
Eric A. Singer, MD, MA, FACS, an expert on bladder cancer
Dr. Diana Magee in an interview with Urology Times
Dr. Brian Chun in an interview with Urology Times
Jacob Taylor, MD, MPH, answers a question during a Zoom video interview
blurred photo of a clinic hallway
Dr. Angela Smith in an interview with Urology Times
Jacob Taylor, MD, MPH, answers a question during a Zoom video interview
Related Content
© 2023 MJH Life Sciences

All rights reserved.